Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

1(50.0%)

Phase 2

1(50.0%)

2Total

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07489274Phase 4Recruiting

Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial).

Role: lead

NCT04691440Phase 2Unknown

Hyperbaric Oxygen Treatment in Humans With Gram Positive Cocci Endocarditis

Role: lead

NCT02501382Completed

Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment

Role: lead

NCT03147352Completed

Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study

Role: lead

NCT02221466Completed

Measurement of Endothelial Function With Peripheral Arterial Tonometry in Patients Undergoing Hyperbaric Oxygen Therapy

Role: lead

NCT02180906Completed

Biomarkers in Patients With Flesh-eating Bacterial Infections

Role: lead

All 6 trials loaded